Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Reports Second Quarter 2001 Results
Bothell, WA — July 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its second quarter ended June 30, 2001. Revenues for the quarter were $35,000, compared to revenues of $36,000 in the second quarter of 2000. For the first six months of 2001, revenues were $35,000,
View HTML
Toggle Summary Seattle Genetics Licenses Monoclonal Antibodies from CLB-Research and Development
Bothell, WA – July 18, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has entered into an agreement to license certain monoclonal antibodies that target cancer and immunological disease from CLB-Research and Development, located in the Netherlands.
View HTML
Toggle Summary Seattle Genetics Announces Date of Second Quarter Results and Conference Call
BOTHELL – July 11, 2001 --- Seattle Genetics (Nasdaq: SGEN) will release second quarter 2001 results on Tuesday, July 24, 2001, after the close of U.S. financial markets. This announcement will be available on the Seattle Genetics website at www.seattlegenetics.com.
View HTML
Toggle Summary Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes
Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has been added to the Russell 2000® and Russell 3000® stock indexes. These Russell Indexes, issued by the Frank Russell Company, are adjusted annually based on market capitalization as of May 31st.
View HTML
Toggle Summary Seattle Genetics Names Morris Rosenberg Vice President, Development
Company expands its product development and clinical manufacturing initiatives Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of Morris Z. Rosenberg as Vice President, Development. Dr. Rosenberg will be responsible for overseeing all aspects of
View HTML
Toggle Summary Seattle Genetics and Eos Biotechnology Collaborate To Develop Next Generation Antibody-Drug Conjugates For Cancer Therapy
Bothell, WA and South San Francisco, CA – June 5, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Eos Biotechnology, Inc. announced today a collaboration to use Seattle Genetics’ toxic payload technology with Eos’ proprietary monoclonal antibodies directed against novel cancer targets derived from
View HTML
Toggle Summary Seattle Genetics Appoints New Members to its Board of Directors and Scientific Advisory Board
Immunex’s Executive Vice President Douglas E. Williams, Ph.D. Added to Board of Directors Noted Cancer Expert Dan L. Longo, M.D. Added to Scientific Advisory Board Bothell, WA – May 17, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of new members to both its Board of
View HTML
Toggle Summary Seattle Genetics Scheduled at CIBC World Markets Bio-Technology Conference
Bothell, WA — May 1, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets First Annual Bio-Technology Conference on May 2, 2001 at 10:25 a.m. Eastern Time.
View HTML
Toggle Summary Seattle Genetics Reports First Quarter Results
Bothell, WA — April 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its first quarter ended March 31, 2001. Net loss for the quarter was $4.2 million, or $0.46 per share, compared to a net loss of $0.9 million, or $.30 per share for the same period in 2000.
View HTML
Toggle Summary Seattle Genetics Announces Initial Public Offering
Bothell, WA – March 7, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the pricing of its initial public offering of 7,000,000 shares of common stock at $7.00 per share. The offering includes a $2 million investment, or 285,714 shares, purchased directly by Genentech, Inc.
View HTML